
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Trends in HIV Care, Part 2: Antiretrovirals in the Pipeline, HIV/Hepatitis C Virus Coinfection, and Pharmacokinetics of Treatment Adherence-A Roundtable Discussion






